VC Funding Top Ten — October 10, 2026: AI Mega-Rounds, Quantum's Big Bet, Biotech IPOs

Overview

Saturday, October tenth. Today's biggest check is a staggering two billion dollars. Axiom Solutions International just locked in a $2B late-stage round, valuing the AI infrastructure provider at a massive $37.5 billion. It's a day defined by huge bets on the foundational layers of artificial intelligence. We'll break d

In this show

• Saturday, October tenth. Today's biggest check is a staggering two billion dollars. Axiom Solutions International just locked in a $2B late-stage round, valuing the AI infrastructure provider at a massive $37.5 billion. It's a day defined by huge bets on the foundational layers of artificial intelligence. We'll break down the top ten deals with our Markets and World analysts. Let's get into the numbers.
• Here is today's snapshot. We tracked $4.43 billion in disclosed funding across just ten rounds. The largest, as mentioned, was Axiom Solutions' two-billion-dollar haul. The hottest category remains AI, accounting for four of the top ten deals. On the public market front, TRex Bio priced its IPO at fourteen dollars per share, the low end of its range. The story of the day is clear: AI infrastructure and foundational models continue to command mega-rounds, with Axiom and TypeSafe AI alone raising a combined $2.87 billion.
• Let's start with that number one deal. Axiom Solutions International, a spinout from manufacturing giant Flex, raised $2 billion in a late-stage round led by General Catalyst and Koch Equity. The deal sets a $37.5 billion enterprise value. Axiom provides critical private cloud and power infrastructure for data centers. This isn't just a funding round; it's a strategic investment signaling intense investor conviction in the picks and shovels needed for the global AI buildout. The capital required to power these models is becoming a market in itself.
• Following that is another AI giant. TypeSafe AI, developer of the popular 'Jev' model, closed an $870 million late-stage round led by Andreessen Horowitz, valuing the company at $7.5 billion. This financing underscores the ongoing frenzy to back potential challengers to the established leaders in foundational AI models. With 'Jev' gaining significant traction among developers and enterprises, this capital injection is aimed squarely at scaling their research and compute capacity to compete at the highest level. The AI arms race for talent and capital continues to heat up.
• In third place, a massive bet on the future of computing itself. Quantum computing startup Oratomic raised a $475 million Series A at a staggering $5.4 billion valuation. The round was led by a syndicate of top-tier firms, including Arch Venture Partners, Spark Capital, and Bezos Expeditions. A Series A of this magnitude for a deep-tech company is rare and indicates that major investors are willing to make significant, long-term bets on foundational technologies that could completely redefine computation and solve problems currently intractable for even the most powerful supercomputers.
• At number four, a solution for one of AI's most pressing problems. SignSplit emerged from stealth with a massive $400 million seed round from W Group, earning it a $1 billion valuation right out of the gate. The company provides tools to protect, license, and verify human-contributed data used for training AI models. This enormous seed round highlights the critical and growing need for solutions that address data provenance and fair compensation in the generative AI era. As regulators and creators scrutinize training data, this market is exploding.
• The fifth largest round goes to Vinci, which is building an AI-native platform for hardware engineers. The company raised a $250 million Series B led by Advent, Temasek, and Xora, pushing its valuation to $1.5 billion. Vinci's platform is designed to dramatically shorten the design and engineering lifecycle for complex physical products, from semiconductors to automotive parts. This funding will accelerate its mission to bring the speed of software development to the world of physical engineering, a massive and historically slow-moving industry.
• At number six, we see the downstream effects of the AI boom. Voltus, an operator of a distributed energy platform, raised a $225 million Series D. The round was led by Generation Investment Management, Activate Capital, and Vitol. As energy demands from data centers and AI computation skyrocket, Voltus's platform becomes increasingly critical. It enhances grid flexibility and efficiency using software. This funding highlights the growing importance of, and investor interest in, smart solutions for managing and optimizing our power grids in the face of unprecedented demand.
• Coming in at number seven is Matchpoint Therapeutics, a biotech firm that raised a $150 million Series B co-led by Nextech Invest and Norwest. The company uses a machine learning platform to discover small-molecule drugs for diseases that have been historically difficult to treat. This financing, which notably includes several pharmaceutical venture arms, is a strong vote of confidence. The capital will be used to advance its lead candidate, an oral T cell modulator for autoimmune conditions, into clinical trials next year, a key milestone for the company.
• At number eight, robotics company Parallel Systems secured a $100 million Series C led by AVP. The company develops autonomous, battery-electric freight rail vehicles designed to make rail transport more flexible. Instead of miles-long trains, they operate in smaller, self-propelled platoons. With this new capital, the company plans to scale production and expand internationally. The goal is to offer a more efficient and environmentally friendly alternative to trucking, especially for the short-haul freight market that traditional rail has struggled to serve effectively.
• Rounding out the top ten, we have two notable deals. First, TeddyHoldings.AI, a legal tech incubation platform, raised a significant $60 million seed round. This suggests a strong market appetite for AI-driven solutions to modernize the legal industry. And second, DataTribe, a venture capital firm focused on cybersecurity and data science, announced the launch of its fourth fund. While the fund size wasn't disclosed, its closing indicates continued investor confidence in early-stage cybersecurity, especially as AI-powered threats create new challenges and market opportunities.
• And now, one thing to watch. The IPO window for biotech appears to be creaking open. Following TRex Bio's pricing, all eyes are now on City Therapeutics, an RNA interference biotech that set terms this week for a potential $175 million IPO. A successful public debut for City Therapeutics could encourage a whole new wave of venture-backed life sciences companies to test the public markets in the coming weeks, which could further thaw a long-frozen IPO market. That's our show. We'll be back tomorrow afternoon at three PM Pacific with the next deal flow.